The online abstracts submission is now closed. Notification of acceptance is December 15, 2022.
All congress activities, including the full Scientific Program, social and networking events will be hosted in-person in Bangkok. The Scientific Program and e-Posters will also be accessible online, via livestream and on-demand.
Accepted abstracts will be presented as posters or e-posters at WCN’23 and they will be published in the Kidney International Reports.
Presenting authors must register and pay their registration by January 11, 2023, to have their abstract presented and published as described above.
Check out the instructions below on how to complete your online submission, and read on for the abstract categories.
Chronic Kidney Disease, Hypertension, Diabetes and CVD
- Chronic Kidney Disease Diagnosis, Classification and Progression
- Chronic Kidney Disease Complications (CVD, Hypertension, Anemia, BMD, Nutrition, Infection)
- Epidemiology, Outcomes and Health Service Research Related to CKD or Its Complications
- Diabetic Kidney Disease, Drugs and Treatments
- Chronic Kidney Disease, Experimental Models, Biomarkers, Precision Medicine
- Vascular Biology and Endothelial Function
- Physiology of Tubular Function and Tubulointerstitial Kidney Disease, Renal Model Systems (Organoids and Kidney on a Chip)
- Essential Hypertension and Renovascular Kidney Disease
- Special Challenges in the Burden and Management of CKD in Developing Countries
- Genetics and Epigenetics (Including Common and Rare Genetic Diseases)
- Inflammation, Fibrosis, Matrix Biology and Oxidative Stress
- Urologic Disorders – Stones, Nephrocalcinosis
- Nephrotic Syndrome
- Other CKD
AKI, Electrolytes, Acid-base Disorders, Tropical Diseases, RPGN and Pregnancy
- Acute Kidney Injury Clinical, Drugs, AKI-CKD Continuum
- Acute Kidney Injury – Mechanisms, Experimental Models and Biomarkers
- Acid-base and Electrolyte Abnormalities in Kidney Disease
- Experimental Models- Glomerulonephritis
- Clinical Glomerulonephritis
- Tropical Kidney Diseases (Viral Nephropathies, TB, Schistosomiasis, Malaria, Leptospirosis, Animal Venoms)
- Kidney in Pregnancy and Post-Partum
- Other AKI
Kidney Failure (Former ESKD), incl. Dialysis, Transplantation, Conservative Care
- Epidemiology, Outcomes and Health Services Research in Dialysis
- Haemodialysis, Haemodiafiltration and Vascular Access
- Peritoneal Dialysis
- Bioethics, Supportive/Palliative Care and Quality of Life in Kidney Failure (Former ESKD)
- Kidney Transplantation and Transplant Immunology
- Other Kidney Failure (Formerly ESKD)
- Covid-19 and AKI
- Covid-19 and CKD
- Covid-19 and Kidney Failure (Former ESKD)
- Social Media
- Online Learning
- Character count: You may use up to 3,400 characters. Spaces are included in the character count (tables and graphs do not count as characters if inserted as an image). Abstract authors/co-authors’ names and affiliations, and keywords do not count towards the 3,400-character allowance.
- Abstracts are structured: Introduction, methods, results, conclusion. Tables, graphs, and pictures may be included (tables and graphs do not count as characters if inserted as an image).
- Images must be in JPEG or PNG format (uploaded images cannot exceed 640w x 480h pixels and 1,5 Megabytes).
- Case reports that present novel hypotheses, pathologies, treatments, or ethical issues are welcome. However, they are only likely to be selected if the originality is highlighted effectively.
- Submitted abstracts must describe unpublished work, which is not already in press and which is not awaiting possible acceptance by any other society/journal. Encore abstracts are not accepted (for exceptions please see update regarding COVID-19 in submission conditions).
- The maximum number of abstract co-authors that can be listed in an abstract is 15.
- Please check carefully for typographical errors, misspellings, poor hyphenation, etc. Please check that your abstract title is correct.
- Abstracts must be submitted in English.
- COVID-19: Because many events have been canceled or made virtual due to the COVID-19 pandemic, abstracts submitted to other meetings in 2022 will exceptionally be accepted. However, abstract authors must declare this at the end of the abstract in the following way: This abstract was also submitted for the (insert meeting title) congress. By submitting the abstract to WCN’23, abstract authors declare that re-submitting the abstract is permitted by the organizers of the previous meeting.
- WCN is a paperless congress. Accepted abstracts will be published electronically in the searchable databases of WCN’23 and Kidney International Reports. No printed abstract book will be produced.
- Presenting authors must register for the congress by January 11, 2023, to have their abstract published as described above and to have a e-poster presentation at the congress. If you have submitted an abstract for the congress, the same congress profile (login identity) must be used to register for the event.
- A non-refundable handling fee of 40 USD is charged per abstract that is submitted. The handling fee must be paid by credit card (American Express, MasterCard, or Visa) at the time of submitting the abstract. Payment by bank transfer is not possible. Abstract handling fees are waived ONLY for submitters from low-income countries as defined by the ISN Low Income list. Click here to view the list. The handling fee for late-breaking clinical trials abstracts is 100 USD and is not waived for submitters from low-income countries. Abstract invoice will be available in the submitting author’s congress profile (section “My Congress Documents”) after payment. The invoicing address can be set up during the online payment process. Invoices are generated automatically once the payment is finalized. It is not possible to change invoicing or invoice data once the payment is finalized. Make sure to update your invoice address and data during the online process.
- If the presenting author is unable to present the abstract, a co-author can take their place, as long as they are registered for the congress. The presenting author must inform the congress secretariat of the change at email@example.com, no later than January 11, 2023. If selected abstract presenters fail to register by January 11, 2023, no abstract will be published, and there will be no e-poster presentation at the congress.
- Once submitted, abstracts cannot be changed or withdrawn.
- All copyrights are assigned to ISN.
- All submitted abstracts will be considered for an e-poster presentation.
- ISN Young Nephrologists Awards: The ISN is offering presenting authors under the age of 40 the opportunity to apply for two (2) Young Nephrologists Awards. These awards will cover travel and accommodation contribution to attend the congress. Each winner will have 8 minutes’ oral abstract presentation during a session at the congress. Application for the award is possible only during the online abstract submission process.
- Organ trafficking and tourism ethics compliance: scientific studies and clinical activities must be performed in keeping with the ethical principles outlined in the Declaration of Istanbul on Organ Trafficking and Transplant Tourism. By submitting an abstract for WCN’23, you state that you have not violated any aspect of the Declaration or associated consensus statements on live donation and research on human subjects.
After your abstract has been submitted, you will receive a confirmation email within two business days. If the email doesn’t appear, please check your spam folder.
If you submitted your abstract on the last day of submission (November 16, 2022) and do not receive confirmation within 48 hours, please email: firstname.lastname@example.org to make sure your abstract has been received.
Abstract authors will be notified of acceptance December 15, 2022.
Late-breaking abstracts cover ground-breaking data that would not otherwise have been presented at WCN’23. If such data are available after the regular abstract deadline, the Scientific Program Working Group will still consider it for presentation.
Late-breaking abstracts describe the latest advances, trial data, and results that have not been previously published or presented and highlight novel and practice-changing studies.
The call for late-breaking abstracts is NOT an extension of the general submission deadline. The submission period is from May 2022, to January 11, 2023.
Late-breaking abstract submitters are required to submit a ‘place holder’ abstract during the regular submission period (deadline November 16, 2022). For further information on updating your abstract, please see “Post-Submission” section below.
Preparing a Late-breaking Abstract Submission:
- Late-breaking abstracts should follow the standard abstract structure: introduction, methods, results and conclusions.
- Late-breaking abstracts should highlight novel and practice-changing studies.
- Late-breaking abstracts will only be considered if a placeholder abstract is submitted during the regular abstract submission period (deadline November 16, 2022). To submit an abstract, please log in to your congress profile and go to “Late-breaking Clinical Trial Abstract(s).”
- A non-refundable handling fee of 100 USD will be charged per abstract submitted in this category. This fee is not waived for applications from low-income countries. Abstract invoices will be available in the submitting author’s congress profile (section “My Congress Documents”) after payment.
- Late-breaking abstracts will be considered for potential oral presentation in one of the sessions at WCN’23.
- The call for late-breaking abstracts is NOT an extension of the submission deadline (November 16, 2022).
- Updating an abstract Please send a letter of intent to email@example.com no later than January 11, 2023.
- The abstract submission portal will temporarily re-open until January 11, 2023 for authors to make updates.